steglujan
merck sharp & dohme b.v. - ertugliflozin l-pyroglutamic kyseliny, sitagliptin fosfát monohydrát - diabetes mellitus, typ 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - steglujan je indikovaný u dospelých vo veku 18 rokov a starších s diabetes mellitus 2. typu ako doplnok stravy a cvičenia na zlepšenie glykemický ovládanie:keď metformínom a/alebo sulfonylmocoviny (su) a jeden z monocomponents z steglujan neposkytujú dostatočnú glykemický ovládanie. u pacientov už liečená kombinácia ertugliflozin a sitagliptin ako samostatné tablety.
rosuvastatin mylan 5 mg
mylan ireland limited, Írsko - rosuvastatín - 31 - hypolipidaemica
rosuvastatin mylan 10 mg
mylan ireland limited, Írsko - rosuvastatín - 31 - hypolipidaemica
rosuvastatin mylan 20 mg
mylan ireland limited, Írsko - rosuvastatín - 31 - hypolipidaemica
rosuvastatin mylan 40 mg
mylan ireland limited, Írsko - rosuvastatín - 31 - hypolipidaemica
atoris 30
krka, d.d., novo mesto, slovinsko - atorvastatín - 31 - hypolipidaemica
sorvasta 5 mg
krka, d.d., novo mesto, slovinsko - rosuvastatín - 31 - hypolipidaemica
abecma
bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastické činidlá - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.
talvey
janssen-cilag international n.v. - talquetamab - viacnásobný myelóm - antineoplastické činidlá - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.
atryn
laboratoire francais du fractionnement et des biotechnologies - antithrombin alfa - nedostatok antitrombínu iii - antitrombotické činidlá - atryn je indikovaný na profylaxiu venózneho tromboembolizmu u pacientov s vrodeným nedostatkom antitrombínu. atryn sa zvyčajne podáva v kombinácii s heparínom alebo heparínom s nízkou molekulovou hmotnosťou.